NATALIE MARSHALL M.D. NPI 1366445470

NPI Details

Natalie Marshall, M.D. is a medical oncology internal medicine in Berkeley, CA with 34 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Natalie Marshall, M.D. NPI is 1366445470. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
Graduation Year:1992

The provider's business location address is:

3100 SAN PABLO AVE.
SUITE 430
BERKELEY, CA
ZIP 94702
Phone: (510) 420-8000
Fax: (510) 985-5202

The NPI 1366445470 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection of drug or substance into vein (HCPCS:96374)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or (HCPCS:G2212)
• Collection of blood sample from implanted device (HCPCS:36591)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)

The enumeration date for this NPI number is 5/23/2005 and was last updated on 10/12/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.